DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro

Movement Disorders

Volumn 29, Issue 13, 2014, Pages 1606-1614

  Coupland, Kirsten G ^a,b   Mellick, George D ^c   Silburn, Peter A ^d   Mather, Karen ^e   Armstrong, Nicola J ^e,f   Sachdev, Perminder S ^e,g   Brodaty, Henry ^e,g   Huang, Yue ^a,b   Halliday, Glenda M ^a,b   Hallupp, Marianne ^a   Kim, Woojin S ^a,b   Dobson Stone, Carol ^a,b   Kwok, John B J ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

DNA methylation; Microtubule associated protein tau; Parkinson's disease; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; TAU PROTEIN; ANTIOXIDANT; MAPT PROTEIN, HUMAN;

ADULT; AGED; ANTERIOR CINGULATE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MICROTUBULE ASSOCIATED PROTEIN TAU GENE; PARKINSON DISEASE; PROMOTER REGION; PUTAMEN; PYROSEQUENCING; BRAIN; COHORT ANALYSIS; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BRAIN; CELL LINE, TUMOR; COHORT STUDIES; DNA METHYLATION; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUROBLASTOMA; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; TAU PROTEINS; TRANSFECTION; VITAMIN E;

EID: 84911391652     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25784     Document Type: Article

References (41)

1. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115:1449-1457.
2. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
3. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012;124:325-338.
4. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-1312.
5. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010;74:97-109.
6. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005;42:837-846.
7. Kwok JB, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004;55:329-334.
8. Skipper L, Wilkes K, Toft M, et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004;75:669-677.
9. Trabzuni D, Wray S, Vandrovcova J, et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet 2012;21:4094-4103.
10. Caffrey TM, Wade-Martins R. Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol Dis 2007;27:1-10.
11. Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 2010;16:7-16.
12. Schofield PN, Joyce JA, Lam WK, Grandjean V, Ferguson-Smith A, Reik W, Maher ER. Genomic imprinting and cancer; new paradigms in the genetics of neoplasia. Toxicol Lett 2001;120:151-160.
13. Kwok JBJ. Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2010;2:671-682.
14. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease [serial online]. PloS One 2009;4:e6617.
15. Jowaed A, Schmitt I, Kaut O, Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010;30:6355-6359.
16. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease [serial online]. PloS One 2010;5:e15522.
17. Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Ukitsu M, Genda Y. The methylation status of cytosines in a tau gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex. Neurosci Lett 1999;275:89-92.
18. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 2009;68:880-891.
19. Sachdev PS, Brodaty H, Reppermund S, et al.; Memory and Ageing Study Team. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int Psychogeriatr 2010;22:1248-1264.
20. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005;58:829-839.
21. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
22. Wong HL, Byun HM, Kwan JM, Campan M, Ingles SA, Laird PW, Yang AS. Rapid and quantitative method of allele-specific DNA methylation analysis. Biotechniques 2006;41:734-739.
23. Klug M, Rehli M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics 2006;1:127-130.
24. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001;308:54-56.
25. Kwok JB, Loy CT, Hamilton G, et al. Glycogen synthase kinase-3 beta and tau genes interact in Alzheimer's disease. Ann Neurol 2008;64:446-454.
26. Pastor P, Ezquerra M, Munoz E, Marti MJ, Blesa R, Tolosa E, Oliva R. Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol 2000;47:242-245.
27. Pankratz N, Wilk JB, Latourelle JC, et al.; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genome wide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009;124:593-605.
28. Boks MP, Derks EM, Weisenberger DJ, et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls [serial online]. PloS One 2009;4:e6767.
29. Haaxma CA, Borm GF, Bloem BR, Horstink MWIM. Gender differences in Parkinson's disease. Mov Disord 2006;21(suppl 14):S84-S84.
30. Schilling E, El Chartouni C, Rehli M. Allele-specific DNA methylation in mouse strains is mainly determined by cis-acting sequences. Genome Res 2009;19:2028-2035.
31. Schalkwyk LC, Meaburn EL, Smith R, et al. Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet 2010;86:196-212.
32. Kerkel K, Spadola A, Yuan E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 2008;40:904-908.
33. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time dependent repression of transcription initiation. Curr Biol 1997;7:157-165.
34. Gillette-Guyonnet S, Secher M, Vellas B. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. Br J Clin Pharmacol 2013;75:738-755.
35. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 2005;4:362-365.
36. Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis 2013;57:38-46.
37. Banzhaf-Strathmann J, Claus R, Mucke O, et al. Promoter DNA methylation regulates progranulin expression and is altered in FTLD. Acta Neuropathol Commun 2013;1:16-16.
38. Switzeny OJ, Mullner E, Wagner KH, Brath H, Aumuller E, Haslberger AG. Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects [serial online]. Clin Epigenet 2012;4:19.
39. Tobin JE, Latourelle JC, Lew MF, et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008;71:28-34.
40. Hayesmoore JBG, Bray NJ, Cross WC, Owen MJ, O'Donovan MC, Morris HR. The effect of age and the H1c MAPT haplotype on MAPT expression. Neurobiol Aging 2009;30:1652-1656.
41. Morris M, Koyama A, Masliah E, Mucke L. Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease [serial online]. PloS One 2011;6:e29257.